Gilead Sciences Deal Activity — 20 Deals Analyzed

Gilead Sciences's Deal Portfolio

Gilead Sciences closed 20 deals between January 2019 and April 2026, with total announced deal value exceeding $18B across the most recent transactions alone. The concentration is unmistakable: oncology and infectious disease dominate the portfolio, but immunology and rare disease have emerged as meaningful secondary pillars — particularly in 2024–2026. This is not a company dabbling. Gilead is making large, thesis-driven bets with escalating conviction.

Three TAs account for the vast majority of capital deployed: oncology (three deals, over $6.9B in combined TDV), infectious disease (a legacy stronghold with continued HBV and antiviral investment), and immunology (the $2.175B gamgertamig deal signals serious intent). The seladelpar acquisition at $4.3B TDV for rare disease is an outlier — but a deliberate one, designed to build a commercial franchise outside Gilead's traditional virology base.

The pattern: Gilead is diversifying aggressively out of infectious disease while still protecting its core. Oncology is the growth thesis. Immunology is the emerging bet. Rare disease is the commercial hedge. For context on how these mega-deal valuations compare, see the mega deals benchmarks.

Deal Type Preferences

Gilead's deal structure mix — acquisitions, licenses, options, co-development, and collaborations — tells you exactly how they think about risk staging. The company doesn't default to one model. It deploys the right structure for the right stage, and the data proves it.

For early-stage assets (preclinical to Phase 1), Gilead favors option structures and co-development agreements. The Nurix opt-in co-development deal and the HBV option deal ($180M upfront) are textbook examples: Gilead buys the right to decide later, paying enough to secure access without committing to full acquisition economics on underegistered assets. The GH31 oncology deal — Phase 1, $80M upfront on $1.53B TDV — shows a 5.2% upfront ratio, meaning Gilead captured massive optionality for relatively modest near-term capital.

For de-risked or platform assets, the acquisitions are large and heavily front-loaded. The Tubulis/TUB-040 tandem totals $10B in TDV. The gamgertamig deal puts $1.675B upfront on a $2.175B total — a 77% upfront ratio. The seladelpar acquisition at $4.3B was an outright buy. When Gilead has conviction, they pay.

The average upfront ratio across the portfolio sits at 43.7% of TDV. That is above the industry median for licensing deals (typically 25–35%) but well within range for a buyer that skews toward acquisitions and late-stage assets. For sellers, this is a credible signal: Gilead will pay meaningful upfront consideration, but they expect commercial-stage data or clear platform value to justify it. If you're Phase 1 with limited data, expect to earn most of your deal value through milestones. Use the Deal Calculator to benchmark where your asset's upfront should land relative to Gilead's historical ratios.

Strategic Pattern

Gilead's deal activity from 2019 to 2026 reveals three interconnected strategic moves, each building on the last.

1. The Oncology Platform Build

This is the headline. The $10B Tubulis deal in April 2026 is not just a pipeline acquisition — it's a platform play. Gilead bought TUB-040 (Phase 2 ADC) and the broader Tubulis ADC platform simultaneously. Combined with the GD2 preclinical deal ($380M TDV) and the GH31 Phase 1 oncology license ($1.53B TDV), Gilead is constructing a multi-modality oncology engine anchored around ADCs and novel targets. This follows the Immunomedics/Trodelvy acquisition logic from 2020 ($21B): Gilead has decided that oncology is its next $10B+ revenue franchise, and it's buying its way in at every stage of the pipeline.

2. The Immunology Entry

The gamgertamig deal ($1.675B upfront, $2.175B TDV) in March 2026 marks Gilead's most aggressive immunology move to date. A Phase 1 asset commanding a 77% upfront ratio is extraordinary — it implies Gilead sees near-term clinical readouts that could accelerate this program rapidly. This isn't an exploratory partnership. This is a conviction buy. Combined with the Nurix co-development, Gilead is building an immunology pipeline from multiple entry points.

3. The Infectious Disease Refresh

Gilead's virology franchise (HIV, HCV, HBV) remains its cash engine, but the deal activity here is maintenance-mode, not growth-mode. The HBV portfolio deal at $100M TDV and the HSV deal at $365M TDV are modest compared to the oncology and immunology expenditures. Gilead is protecting its base — not expanding it. The HBV option deal ($180M upfront with no disclosed TDV) gives them a call on cure-oriented HBV assets without betting the balance sheet on a therapeutic area where multiple competitors have stalled in late-stage development.

The thesis: Gilead is executing a controlled portfolio rotation — from an infectious disease cash cow into a diversified biopharma with anchor franchises in oncology and immunology, while using rare disease (seladelpar) as a near-term commercial bridge.

What This Means If You're Pitching to Gilead Sciences

If you're a biotech founder or BD lead preparing to approach Gilead, here's what the data says you need to know.

• Sweet spot assets: Oncology (especially ADCs, novel targets, tumor-agnostic mechanisms), immunology (autoimmune, inflammatory — differentiated MOAs), and infectious disease (only if you have a functional cure angle for HBV or a truly novel antiviral). Rare disease and gastroenterology are secondary; don't lead with those unless you're Phase 3 with a clean regulatory path.
• Stage matters for structure: If you're preclinical or Phase 1, propose an option or co-development deal. Gilead will not acquire you outright at this stage unless you have platform technology (see: Tubulis). Expect $35M–$80M upfront with milestone-heavy TDVs in the $300M–$1.5B range. If you're Phase 2+ with differentiated data, you're in acquisition territory. Come with a number north of $2B TDV and be prepared to justify the upfront ask with clinical evidence.
• Upfront expectations: At 43.7% average, Gilead pays more upfront than many large-cap buyers. But that average is skewed by their late-stage acquisitions. For early-stage licenses, model 5–15% upfront. For Phase 2+ assets, model 50–77%. The Partner Matching engine can score your asset against Gilead's historical deal parameters.
• What they'll push back on: Gilead will resist large upfronts for Phase 1 assets without a clear clinical differentiation story. They'll push for opt-in structures where they fund your development in exchange for acquisition rights at pre-agreed terms. They'll also push for broad rights — global, exclusive, multi-indication. If you want to retain geography or indication carve-outs, bring competitive tension from other buyers.
• Timing: Gilead's 2026 deal activity is the most aggressive in the company's history. Five deals announced in the first four months of 2026, representing over $14B in TDV. This pace suggests Gilead has internal pressure to fill the pipeline before HIV revenue declines accelerate. If you have an asset that fits their thesis, the window is open — arguably wider than it's been in a decade.

Frequently Asked Questions

What therapeutic areas dominate Gilead Sciences deal activity?

Oncology is the clear priority, with three recent deals totaling over $6.9B in combined TDV, including the $5B Tubulis ADC platform acquisition. Immunology is the fastest-growing area of interest, highlighted by the $2.175B gamgertamig deal in March 2026. Infectious disease remains active but at lower TDVs — deals in 2024–2025 ranged from $100M to $365M. Rare disease and gastroenterology are opportunistic rather than systematic.

What upfront payment should biotechs expect from Gilead?

Gilead's average upfront ratio is 43.7% of TDV — higher than the typical large-pharma buyer. However, this ratio varies dramatically by stage: Phase 1 assets have received as little as 5.2% upfront (GH31: $80M on $1.53B TDV), while conviction buys like gamgertamig commanded 77% ($1.675B on $2.175B). Preclinical oncology assets (GD2) received approximately 10.8% upfront. Biotechs should model stage-appropriate ratios rather than relying on the blended average.

Does Gilead prefer acquisitions or licensing deals?

Gilead uses both, but the decision hinges on asset maturity and platform value. For Phase 2+ assets and technology platforms, Gilead defaults to outright acquisition — the Tubulis and seladelpar deals are clear examples. For earlier-stage assets, Gilead prefers option agreements and co-development structures that preserve flexibility, as seen in the Nurix and HBV option deals. The company executed deals across all six structure types (acquisition, license, option, co-development, collaboration, other) in the 2019–2026 period.

How has Gilead Sciences licensing activity changed in 2026?

Gilead Sciences licensing deals in 2026 represent a dramatic escalation. The company announced five deals in the first four months of the year, with combined TDV exceeding $14B — more than the previous two years combined. The Tubulis acquisition alone ($5B TDV for the platform, $5B TDV for TUB-040) is the company's largest non-M&A transaction in this period. The 2026 pace suggests Gilead is in an active buying cycle, likely driven by the need to diversify revenue ahead of longer-term HIV patent exposures.

If your asset fits the profile Gilead is buying — oncology platforms, differentiated immunology mechanisms, or functional-cure virology — this is the time to test the market. Use the Ambrosia calculator's partner matching engine to score your asset against 850+ companies, including Gilead, and identify which buyers align with your therapeutic area, stage, and deal structure preferences.